{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:19:55Z","timestamp":1793834395965,"version":"4.6.1"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","award":["Support for third-party writing assistance for this manuscript"],"award-info":[{"award-number":["Support for third-party writing assistance for this manuscript"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s12325-017-0612-x","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T02:10:24Z","timestamp":1507169424000},"page":"2232-2273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":578,"title":["Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"issue":"Suppl 4","key":"612_CR1","doi-asserted-by":"crossref","first-page":"iv27","DOI":"10.1093\/annonc\/mdr167","volume":"22","author":"P Boffetta","year":"2011","unstructured":"Boffetta P. Epidemiology of adult non-Hodgkin lymphoma. Ann Oncol. 2011;22(Suppl 4):iv27\u201331.","journal-title":"Ann Oncol"},{"key":"612_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/ajh.23979","volume":"90","author":"M Hallek","year":"2015","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:447\u201360.","journal-title":"Am J Hematol"},{"key":"612_CR3","unstructured":"National Cancer Institute. SEER cancer statistics review 1975\u20132013. Non-Hodgkin lymphoma. 2016. https:\/\/seer.cancer.gov\/csr\/1975_2013\/results_merged\/sect_19_nhl.pdf . Accessed 21 Jun 2017."},{"key":"612_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"612_CR5","doi-asserted-by":"publisher","first-page":"6524","DOI":"10.1038\/sj.onc.1207843","volume":"23","author":"SG Fisher","year":"2004","unstructured":"Fisher SG, Fisher RI. The epidemiology of non-Hodgkin\u2019s lymphoma. Oncogene. 2004;23:6524\u201334.","journal-title":"Oncogene"},{"key":"612_CR6","unstructured":"Cancer Research UK. Non-Hodgkin lymphoma (C82-C86): 1979-2013 European age-standardised incidence rates per 100,000 population, by sex, Great Britain. 2013. http:\/\/www.cancerresearchuk.org\/sites\/default\/files\/cstream-node\/inc_asr_gb_nhl_1.pdf . Accessed 21 Jun 2017."},{"key":"612_CR7","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Non-Hodgkin Lymphoma. 2017. http:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html . Accessed 21 Jun 2017."},{"key":"612_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","volume":"35","author":"Q Chen","year":"2017","unstructured":"Chen Q, Jain N, Ayer T, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35:166\u201374.","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"612_CR9","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116\u201325.","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"612_CR10","doi-asserted-by":"publisher","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","volume":"27","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v83\u201390.","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"612_CR11","doi-asserted-by":"publisher","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","volume":"26","author":"B Eichhorst","year":"2015","unstructured":"Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v78\u201384.","journal-title":"Ann Oncol"},{"key":"612_CR12","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558\u201365.","journal-title":"Blood"},{"key":"612_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","volume":"17","author":"International CLL-IPI Working Group","year":"2016","unstructured":"International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779\u201390.","journal-title":"Lancet Oncol"},{"key":"612_CR14","doi-asserted-by":"publisher","first-page":"13520","DOI":"10.1073\/pnas.0804295105","volume":"105","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105:13520\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"612_CR15","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","volume":"33","author":"DW Scott","year":"2015","unstructured":"Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33:2848\u201356.","journal-title":"J Clin Oncol"},{"key":"612_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495\u20137.","journal-title":"Nature"},{"key":"612_CR17","unstructured":"National Cancer Institute. Using the immune system in the fight against cancer: discovery of rituximab. 2014. http:\/\/www.cancer.gov\/research\/progress\/discovery\/blood-cancer . Accessed 21 Jun 2017."},{"key":"612_CR18","first-page":"3147","volume":"40","author":"LM Nadler","year":"1980","unstructured":"Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980;40:3147\u201354.","journal-title":"Cancer Res"},{"key":"612_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJM198203043060906","volume":"306","author":"RA Miller","year":"1982","unstructured":"Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517\u201322.","journal-title":"N Engl J Med"},{"key":"612_CR20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","volume":"69","author":"OW Press","year":"1987","unstructured":"Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987;69:584\u201391.","journal-title":"Blood"},{"key":"612_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0065-2776(08)60876-7","volume":"52","author":"J Banchereau","year":"1992","unstructured":"Banchereau J, Rousset F. Human B lymphocytes: phenotype, proliferation, and differentiation. Adv Immunol. 1992;52:125\u2013262.","journal-title":"Adv Immunol"},{"key":"612_CR22","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. B-cell lymphomas. Version 3.2016. 2016. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site . Accessed 21 Jun 2017."},{"key":"612_CR23","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Chronic lymphocytic leukemia\/small lymphocytic lymphoma. Version 1.2017. 2017. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site . Accessed 21 Jun 2017."},{"key":"612_CR24","unstructured":"World Health Organization. WHO Model Lists of Essential Medicines, adults. 20th edn. 2017. http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/ . Accessed 21 Jun 2017."},{"key":"612_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S1470-2045(14)70005-1","volume":"15","author":"A Davies","year":"2014","unstructured":"Davies A, Merli F, Mihaljevic B, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014;15:343\u201352.","journal-title":"Lancet Oncol"},{"key":"612_CR26","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1016\/S2352-3026(16)00004-1","volume":"3","author":"S Assouline","year":"2016","unstructured":"Assouline S, Buccheri V, Delmer A, et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol. 2016;3:e128\u201338.","journal-title":"Lancet Haematol"},{"issue":"Suppl 3","key":"612_CR27","doi-asserted-by":"publisher","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","volume":"25","author":"M Dreyling","year":"2014","unstructured":"Dreyling M, Geisler C, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii83\u201392.","journal-title":"Ann Oncol"},{"key":"612_CR28","first-page":"CD007356","volume":"1","author":"MA Lopez-Olivo","year":"2015","unstructured":"Lopez-Olivo MA, Amezaga Urruela M, McGahan L, Pollono EN, Suarez-Almazor ME. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev. 2015;1:CD007356.","journal-title":"Cochrane Database Syst Rev"},{"key":"612_CR29","unstructured":"Mabthera 100\u00a0mg concentrate for solution for infusion [summary of product characteristics]. Roche Products, Welwyn Garden City. 2017. https:\/\/www.medicines.org.uk\/emc\/medicine\/2570 . Accessed 18 Sept 2017."},{"key":"612_CR30","unstructured":"Rituxan\u00ae (rituximab) injection, for intravenous use. Genentech, South San Francisco. 2016. https:\/\/www.gene.com\/download\/pdf\/rituxan_prescribing.pdf . Accessed 21 Jun 2017."},{"key":"612_CR31","doi-asserted-by":"crossref","unstructured":"Davies A, Berge C, Boehnke A, et al. Subcutaneous rituximab for the treatment of B-cell hematological malignancies: scientific rationale and clinical development. Adv Ther. 2017.","DOI":"10.1007\/s12325-017-0610-z"},{"key":"612_CR32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435\u201345.","journal-title":"Blood"},{"issue":"1 Suppl 2","key":"612_CR33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/sonc.2002.30156","volume":"29","author":"DG Maloney","year":"2002","unstructured":"Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29(1 Suppl 2):2\u20139.","journal-title":"Semin Oncol"},{"key":"612_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115\u201323.","journal-title":"Semin Hematol"},{"key":"612_CR35","first-page":"676","volume":"2","author":"P Boross","year":"2012","unstructured":"Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Clin Res. 2012;2:676\u201390.","journal-title":"Am J Clin Res"},{"key":"612_CR36","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.2217\/fon.14.146","volume":"10","author":"A Abulayha","year":"2014","unstructured":"Abulayha A, Bredan A, El Enshasy H, Daniels I. Rituximab: modes of action, remaining dispute and future perspective. Future Oncol. 2014;10:2481\u201392.","journal-title":"Future Oncol"},{"key":"612_CR37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/blood.V106.11.348.348","volume":"106","author":"GJ Weiner","year":"2005","unstructured":"Weiner GJ, Bowles JA, Link BK, et al. Anti-CD20 monoclonal antibody (mAb) with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2005;106:348.","journal-title":"Blood"},{"key":"612_CR38","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"DG Maloney","year":"1994","unstructured":"Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457\u201366.","journal-title":"Blood"},{"key":"612_CR39","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood. 1997;90:2188\u201395.","journal-title":"Blood"},{"key":"612_CR40","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"NL Berinstein","year":"1998","unstructured":"Berinstein NL, Grillo-L\u00f3pez AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol. 1998;9:995\u20131001.","journal-title":"Ann Oncol"},{"key":"612_CR41","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/01.ftd.0000184162.60197.c1","volume":"27","author":"MB Regazzi","year":"2005","unstructured":"Regazzi MB, Iacona I, Avanzini MA, et al. Pharmacokinetic behaviour of rituximab. A study of different schedules of administration for heterogenous clinical settings. Ther Drug Monit. 2005;27:785\u201392.","journal-title":"Ther Drug Monit"},{"key":"612_CR42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3233\/HAB-2010-0215","volume":"19","author":"L Tran","year":"2010","unstructured":"Tran L, Baars JW, Aarden L, Beijnen JH, Huitema AD. Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Hum Antib. 2010;19:7\u201313.","journal-title":"Hum Antib"},{"key":"612_CR43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1472-8206.2009.00714.x","volume":"23","author":"H Blasco","year":"2009","unstructured":"Blasco H, Chatelut E, Benz de Bretagne I, Congy-Jolivet N, Le Guellec C. Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Fundam Clin Pharmacol. 2009;23:601\u20138.","journal-title":"Fundam Clin Pharmacol"},{"key":"612_CR44","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1182\/blood-2006-10-055087","volume":"110","author":"L Li","year":"2007","unstructured":"Li L, Levi M, Charoin J-E, et al. Rituximab exhibits a long half-life based on a population pharmacokinetic analysis in non-Hodgkin\u2019s lymphoma (NHL) patients. Blood. 2007;110:2371.","journal-title":"Blood"},{"key":"612_CR45","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1177\/0091270011430506","volume":"52","author":"J Li","year":"2012","unstructured":"Li J, Zhi J, Wenger M, et al. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol. 2012;52:1918\u201326.","journal-title":"J Clin Pharmacol"},{"key":"612_CR46","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/annonc\/mdh176","volume":"15","author":"K Tobinai","year":"2004","unstructured":"Tobinai K, Igarashi T, Itoh K, et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol. 2004;15:821\u201330.","journal-title":"Ann Oncol"},{"key":"612_CR47","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2008-08-175125","volume":"113","author":"D Dayd\u00e9","year":"2009","unstructured":"Dayd\u00e9 D, Ternant D, Ohresser M, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood. 2009;113:3765\u201372.","journal-title":"Blood"},{"key":"612_CR48","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/annonc\/mdf155","volume":"13","author":"T Igarashi","year":"2002","unstructured":"Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol. 2002;13:928\u201343.","journal-title":"Ann Oncol"},{"key":"612_CR49","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3324\/haematol.2011.059246","volume":"97","author":"U J\u00e4ger","year":"2012","unstructured":"J\u00e4ger U, Fridrik M, Zeitlinger M, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012;97:1431\u20138.","journal-title":"Haematologica"},{"key":"612_CR50","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1182\/blood-2016-10-744292","volume":"129","author":"M Tout","year":"2017","unstructured":"Tout M, Casasnovas O, Meignan M, et al. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood. 2017;129:2616\u201323.","journal-title":"Blood"},{"key":"612_CR51","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","volume":"119","author":"C M\u00fcller","year":"2012","unstructured":"M\u00fcller C, Murawski N, Wiesen MH, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119:3276\u201384.","journal-title":"Blood"},{"key":"612_CR52","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","volume":"123","author":"M Pfreundschuh","year":"2014","unstructured":"Pfreundschuh M, M\u00fcller C, Zeynalova S, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123:640\u20136.","journal-title":"Blood"},{"key":"612_CR53","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/leu.2014.251","volume":"29","author":"HR Junl\u00e9n","year":"2015","unstructured":"Junl\u00e9n HR, Peterson S, Kimby E, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia. 2015;29:668\u201376.","journal-title":"Leukemia"},{"key":"612_CR54","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825\u201333.","journal-title":"J Clin Oncol"},{"key":"612_CR55","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","volume":"17","author":"TA Davis","year":"1999","unstructured":"Davis TA, White CA, Grillo-L\u00f3pez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin\u2019s lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999;17:1851\u20137.","journal-title":"J Clin Oncol"},{"key":"612_CR56","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s002770000163","volume":"79","author":"M Feuring-Buske","year":"2000","unstructured":"Feuring-Buske M, Kneba M, Unterhalt M, et al. IDECC2B8 (rituximab) anti-CD20 antibody treatment in relapsed relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol. 2000;79:493\u2013500.","journal-title":"Ann Hematol"},{"key":"612_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1046\/j.1365-2141.2000.01965.x","volume":"109","author":"JM Foran","year":"2000","unstructured":"Foran JM, Gupta RK, Cunningham D, et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol. 2000;109:81\u20138.","journal-title":"Br J Haematol"},{"key":"612_CR58","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1023\/A:1008389119525","volume":"10","author":"LD Piro","year":"1999","unstructured":"Piro LD, White CA, Grillo-L\u00f3pez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol. 1999;10:655\u201361.","journal-title":"Ann Oncol"},{"key":"612_CR59","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1093\/annonc\/mds177","volume":"23","author":"P Colombat","year":"2012","unstructured":"Colombat P, Brousse N, Salles G, et al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol. 2012;23:2380\u20135.","journal-title":"Ann Oncol"},{"key":"612_CR60","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1200\/JCO.2015.61.3968","volume":"34","author":"C Taverna","year":"2016","unstructured":"Taverna C, Martinelli G, Hitz F, et al. Rituximab maintenance for a maximum of 5\u00a0years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35\/03. J Clin Oncol. 2016;34:495\u2013500.","journal-title":"J Clin Oncol"},{"key":"612_CR61","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.3109\/10428194.2015.1014363","volume":"56","author":"E Kimby","year":"2015","unstructured":"Kimby E, Ostenstad B, Brown P, et al. Two courses of four\u00a0weekly infusions of rituximab with or without interferon-\u03b12a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. Leuk Lymphoma. 2015;56:2598\u2013607.","journal-title":"Leuk Lymphoma"},{"key":"612_CR62","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","volume":"22","author":"MS Czuczman","year":"2004","unstructured":"Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin\u2019s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711\u20136.","journal-title":"J Clin Oncol"},{"key":"612_CR63","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725\u201332.","journal-title":"Blood"},{"key":"612_CR64","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group hematology and oncology study. J Clin Oncol. 2007;25:1986\u201392.","journal-title":"J Clin Oncol"},{"key":"612_CR65","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417\u201323.","journal-title":"Blood"},{"key":"612_CR66","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26:4579\u201386.","journal-title":"J Clin Oncol"},{"key":"612_CR67","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","volume":"112","author":"G Salles","year":"2008","unstructured":"Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112:4824\u201331.","journal-title":"Blood"},{"key":"612_CR68","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","volume":"98","author":"E Bachy","year":"2013","unstructured":"Bachy E, Houot R, Morschhauser F, et al. Long-term follow-up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica. 2013;98:1107\u201314.","journal-title":"Haematologica"},{"key":"612_CR69","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31:1506\u201313.","journal-title":"J Clin Oncol"},{"key":"612_CR70","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"612_CR71","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH Oers van","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295\u2013301.","journal-title":"Blood"},{"key":"612_CR72","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","volume":"27","author":"H Hochster","year":"2009","unstructured":"Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol. 2009;27:1607\u201314.","journal-title":"J Clin Oncol"},{"key":"612_CR73","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42\u201351.","journal-title":"Lancet"},{"key":"612_CR74","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V122.21.509.509","volume":"122","author":"GA Salles","year":"2013","unstructured":"Salles GA, Seymour JF, Feugier P, et al. Updated 6-year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Blood. 2013;122:509.","journal-title":"Blood"},{"key":"612_CR75","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","volume":"32","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol. 2014;32:3096\u2013102.","journal-title":"J Clin Oncol"},{"key":"612_CR76","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064\u201371.","journal-title":"Blood"},{"key":"612_CR77","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003\u20138.","journal-title":"Blood"},{"key":"612_CR78","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH Oers van","year":"2010","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28:2853\u20138.","journal-title":"J Clin Oncol"},{"key":"612_CR79","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","volume":"28","author":"G Martinelli","year":"2010","unstructured":"Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98. J Clin Oncol. 2010;28:4480\u20134.","journal-title":"J Clin Oncol"},{"key":"612_CR80","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ejca.2017.01.021","volume":"76","author":"L Vidal","year":"2017","unstructured":"Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance improves overall survival of patients with follicular lymphoma\u2013Individual patient data meta-analysis. Eur J Cancer. 2017;76:216\u201325.","journal-title":"Eur J Cancer"},{"key":"612_CR81","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/BF03261894","volume":"26","author":"FB Hagemeister","year":"2012","unstructured":"Hagemeister FB. \u2018Watch and wait\u2019 as initial management for patients with follicular lymphomas: still a viable strategy? BioDrugs. 2012;26:363\u201376.","journal-title":"BioDrugs"},{"key":"612_CR82","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15:424\u201335.","journal-title":"Lancet Oncol"},{"key":"612_CR83","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2015-11-632745","volume":"127","author":"JO Armitage","year":"2016","unstructured":"Armitage JO, Longo DL. Is watch and wait still acceptable for patients with low-grade follicular lymphoma? Blood. 2016;127:2804\u20138.","journal-title":"Blood"},{"key":"612_CR84","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","volume":"19","author":"JM Vose","year":"2001","unstructured":"Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2001;19:389\u201397.","journal-title":"J Clin Oncol"},{"key":"612_CR85","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"key":"612_CR86","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121\u20137.","journal-title":"J Clin Oncol"},{"key":"612_CR87","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379\u201391.","journal-title":"Lancet Oncol"},{"key":"612_CR88","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013\u201322.","journal-title":"Lancet Oncol"},{"key":"612_CR89","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2005;23:4117\u201326.","journal-title":"J Clin Oncol"},{"key":"612_CR90","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116:2040\u20135.","journal-title":"Blood"},{"key":"612_CR91","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3324\/haematol.2015.125344","volume":"100","author":"U Jaeger","year":"2015","unstructured":"Jaeger U, Trneny M, Melzer H, et al. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. Haematologica. 2015;100:955\u201363.","journal-title":"Haematologica"},{"key":"612_CR92","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927\u201332.","journal-title":"Blood"},{"key":"612_CR93","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1182\/blood-2007-08-108415","volume":"111","author":"E Vellenga","year":"2008","unstructured":"Vellenga E, van Putten WLJ, van \u2018t Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed\/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008;111:537\u201343.","journal-title":"Blood"},{"key":"612_CR94","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184\u201390.","journal-title":"J Clin Oncol"},{"key":"612_CR95","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/annonc\/mdh093","volume":"15","author":"M Jermann","year":"2004","unstructured":"Jermann M, Jost LM, Taverna C, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol. 2004;15:511\u20136.","journal-title":"Ann Oncol"},{"key":"612_CR96","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","volume":"103","author":"T Kewalramani","year":"2004","unstructured":"Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684\u20138.","journal-title":"Blood"},{"key":"612_CR97","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1080\/10428190600926572","volume":"47","author":"UJ Mey","year":"2006","unstructured":"Mey UJ, Olivieri A, Orlopp KS, et al. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma. 2006;47:2558\u201366.","journal-title":"Leuk Lymphoma"},{"key":"612_CR98","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3109\/10428194.2012.656629","volume":"53","author":"RL Elstrom","year":"2012","unstructured":"Elstrom RL, Andemariam B, Martin P, et al. Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemo- immunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53:1469\u201373.","journal-title":"Leuk Lymphoma"},{"key":"612_CR99","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164\u201374.","journal-title":"Lancet"},{"key":"612_CR100","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","volume":"28","author":"T Robak","year":"2010","unstructured":"Robak T, Dmoszynska A, Solal-C\u00e9ligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756\u201365.","journal-title":"J Clin Oncol"},{"key":"612_CR101","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","volume":"19","author":"JC Byrd","year":"2001","unstructured":"Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153\u201364.","journal-title":"J Clin Oncol"},{"key":"612_CR102","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","volume":"19","author":"SM O\u2019Brien","year":"2001","unstructured":"O\u2019Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165\u201370.","journal-title":"J Clin Oncol"},{"key":"612_CR103","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1182\/blood-2002-03-0972","volume":"100","author":"H Schulz","year":"2002","unstructured":"Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002;100:3115\u201320.","journal-title":"Blood"},{"key":"612_CR104","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","volume":"101","author":"JC Byrd","year":"2003","unstructured":"Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6\u201314.","journal-title":"Blood"},{"key":"612_CR105","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","volume":"23","author":"MJ Keating","year":"2005","unstructured":"Keating MJ, O\u2019Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079\u201388.","journal-title":"J Clin Oncol"},{"key":"612_CR106","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","volume":"23","author":"W Wierda","year":"2005","unstructured":"Wierda W, O\u2019Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070\u20138.","journal-title":"J Clin Oncol"},{"key":"612_CR107","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","volume":"127","author":"K Fischer","year":"2016","unstructured":"Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208\u201315.","journal-title":"Blood"},{"key":"612_CR108","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","volume":"126","author":"D Rossi","year":"2015","unstructured":"Rossi D, Terzi-di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126:1921\u20134.","journal-title":"Blood"},{"key":"612_CR109","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","volume":"127","author":"P Thompson","year":"2016","unstructured":"Thompson P, Tam CS, O\u2019Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303\u20139.","journal-title":"Blood"},{"key":"612_CR110","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, O\u2019Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975\u201380.","journal-title":"Blood"},{"key":"612_CR111","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO.2008.17.2619","volume":"27","author":"KA Foon","year":"2009","unstructured":"Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high-dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:498\u2013503.","journal-title":"J Clin Oncol"},{"key":"612_CR112","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1182\/blood-2012-01-408047","volume":"119","author":"KA Foon","year":"2012","unstructured":"Foon KA, Mehta D, Lentzsch S, et al. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood. 2012;119:3184\u20135.","journal-title":"Blood"},{"key":"612_CR113","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","volume":"29","author":"JA Woyach","year":"2011","unstructured":"Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011;29:1349\u201355.","journal-title":"J Clin Oncol"},{"key":"612_CR114","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","volume":"29","author":"K Fischer","year":"2011","unstructured":"Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29:3559\u201366.","journal-title":"J Clin Oncol"},{"key":"612_CR115","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","volume":"30","author":"K Fischer","year":"2012","unstructured":"Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209\u201316.","journal-title":"J Clin Oncol"},{"key":"612_CR116","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928\u201342.","journal-title":"Lancet Oncol"},{"key":"612_CR117","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ajh.23668","volume":"89","author":"R Fo\u00e0","year":"2014","unstructured":"Fo\u00e0 R, Del Giudice I, Cuneo A, et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014;89:480\u20136.","journal-title":"Am J Hematol"},{"key":"612_CR118","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1200\/JCO.2013.49.6547","volume":"32","author":"P Hillmen","year":"2014","unstructured":"Hillmen P, Gribben JG, Follows GA, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol. 2014;32:1236\u201341.","journal-title":"J Clin Oncol"},{"key":"612_CR119","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/cncr.23144","volume":"112","author":"G Poeta Del","year":"2008","unstructured":"Del Poeta G, Del Principe MI, Buccisano F, et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer. 2008;112:119\u201328.","journal-title":"Cancer"},{"key":"612_CR120","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood-2013-05-502773","volume":"122","author":"P Abrisqueta","year":"2013","unstructured":"Abrisqueta P, Villamor N, Terol MJ, et al. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood. 2013;122:3951\u20139.","journal-title":"Blood"},{"issue":"15 Suppl","key":"612_CR121","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2016.34.15_suppl.7505","volume":"34","author":"C Dartigeas","year":"2016","unstructured":"Dartigeas C, van den Neste E, Maisonneuve H, et al. Rituximab maintenance after induction with abbreviated FCR in previously untreated elderly (\u226565\u00a0years) CLL patients: results of the randomized CLL 2007 SA trial from the French FILO Group (NCT00645606). J Clin Oncol. 2016;34(15 Suppl):7505.","journal-title":"J Clin Oncol"},{"key":"612_CR122","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/bjh.14181","volume":"175","author":"FT Awan","year":"2016","unstructured":"Awan FT, Gore L, Gao L, Sharma J, Lager J, Costa LJ. Phase Ib trial of the PI3K\/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies. Br J Haematol. 2016;175:55\u201365.","journal-title":"Br J Haematol"},{"key":"612_CR123","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","volume":"17","author":"A Chanan-Khan","year":"2016","unstructured":"Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200\u201311.","journal-title":"Lancet Oncol"},{"key":"612_CR124","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","volume":"56","author":"TJ Kipps","year":"2015","unstructured":"Kipps TJ, Eradat H, Grosicki S, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56:2826\u201333.","journal-title":"Leuk Lymphoma"},{"key":"612_CR125","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1358\/dot.2016.52.4.2470954","volume":"52","author":"G Poeta Del","year":"2016","unstructured":"Del Poeta G, Postorino M, Pupo L, et al. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. Drugs Today. 2016;52:249\u201360.","journal-title":"Drugs Today"},{"key":"612_CR126","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","volume":"35","author":"E Zucca","year":"2017","unstructured":"Zucca E, Conconi A, Martinelli G, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35:1905\u201312.","journal-title":"J Clin Oncol"},{"key":"612_CR127","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjh.14007","volume":"173","author":"ME Williams","year":"2016","unstructured":"Williams ME, Hong F, Gascoyne RD, et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group protocol E4402. Br J Haematol. 2016;173:867\u201375.","journal-title":"Br J Haematol"},{"key":"612_CR128","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","volume":"375","author":"S Maury","year":"2016","unstructured":"Maury S, Chevret S, Thomas X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375:1044\u201353.","journal-title":"N Engl J Med"},{"key":"612_CR129","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","volume":"387","author":"V Ribrag","year":"2016","unstructured":"Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt\u2019s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:2402\u201311.","journal-title":"Lancet"},{"key":"612_CR130","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","volume":"118","author":"R Griffiths","year":"2011","unstructured":"Griffiths R, Mikhael J, Gleeson M, et al. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood. 2011;118:4808\u201316.","journal-title":"Blood"},{"key":"612_CR131","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1200920","volume":"367","author":"HC Kluin-Nelemans","year":"2012","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520\u201331.","journal-title":"N Engl J Med"},{"key":"612_CR132","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","volume":"25","author":"MA Dimopoulos","year":"2007","unstructured":"Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstr\u00f6m macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25:3344\u20139.","journal-title":"J Clin Oncol"},{"key":"612_CR133","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/cncr.23237","volume":"112","author":"Y Oki","year":"2008","unstructured":"Oki Y, Pro B, Fayad LE, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer. 2008;112:831\u20136.","journal-title":"Cancer"},{"key":"612_CR134","doi-asserted-by":"publisher","unstructured":"Trappe RU, Dierickx D, Zimmermann H, et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol. 2016. doi: 10.1200\/JCO.2016.69.3564 .","DOI":"10.1200\/JCO.2016.69.3564"},{"key":"612_CR135","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis TA, Grillo-L\u00f3pez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135\u201343.","journal-title":"J Clin Oncol"},{"key":"612_CR136","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","volume":"24","author":"AR Rezvani","year":"2011","unstructured":"Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol. 2011;24:203\u201316.","journal-title":"Best Pract Res Clin Haematol"},{"key":"612_CR137","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1053\/j.seminoncol.2014.08.006","volume":"41","author":"B Bonavida","year":"2014","unstructured":"Bonavida B. Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. Semin Oncol. 2014;41:667\u201377.","journal-title":"Semin Oncol"},{"key":"612_CR138","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","volume":"14","author":"MS Czuczman","year":"2008","unstructured":"Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14:1561\u201370.","journal-title":"Clin Cancer Res"},{"key":"612_CR139","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","volume":"113","author":"J Hiraga","year":"2009","unstructured":"Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113:4885\u201393.","journal-title":"Blood"},{"key":"612_CR140","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.4049\/jimmunol.1101189","volume":"187","author":"PV Beum","year":"2011","unstructured":"Beum PV, Peek EM, Lindorfer MA, et al. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol. 2011;187:3438\u201347.","journal-title":"J Immunol"},{"key":"612_CR141","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.2012.42.8623","volume":"31","author":"XC Badoux","year":"2013","unstructured":"Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013;31:584\u201391.","journal-title":"J Clin Oncol"},{"key":"612_CR142","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.3109\/10428194.2014.889822","volume":"55","author":"V Ivanov","year":"2014","unstructured":"Ivanov V, Coso D, Chetaille B, et al. Efficacy and safety of lenalidomide combined with rituximab in patients with relapsed\/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55:2508\u201313.","journal-title":"Leuk Lymphoma"},{"key":"612_CR143","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-14-2221","volume":"21","author":"EA Chong","year":"2015","unstructured":"Chong EA, Ahmadi T, Aqui NA, et al. Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas. Clin Cancer Res. 2015;21:1835\u201342.","journal-title":"Clin Cancer Res"},{"key":"612_CR144","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","volume":"33","author":"JP Leonard","year":"2015","unstructured":"Leonard JP, Jung SH, Johnson J, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33:3635\u201340.","journal-title":"J Clin Oncol"},{"key":"612_CR145","unstructured":"Gazyvaro\u00ae 1000 mg concentrate for solution for infusion [summary of product characteristics]. Roche Products, Welwyn Garden City. 2016. http:\/\/www.medicines.org.uk\/emc\/medicine\/29057 . Accessed 1 Jun 2017."},{"issue":"15 Suppl","key":"612_CR146","doi-asserted-by":"crossref","first-page":"10507","DOI":"10.1200\/JCO.2016.34.15_suppl.10507","volume":"34","author":"V Minard-Colin","year":"2016","unstructured":"Minard-Colin V, Auperin A, Pillon M, et al. Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. J Clin Oncol. 2016;34(15 Suppl):10507.","journal-title":"J Clin Oncol"},{"key":"612_CR147","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/11314070-000000000-00000","volume":"28","author":"E Deconinck","year":"2010","unstructured":"Deconinck E, Miadi-Fargier H, Pen CL, Brice P. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoeconomics. 2010;28:35\u201346.","journal-title":"Pharmacoeconomics"},{"key":"612_CR148","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1524-4733.2009.00676.x","volume":"13","author":"JA Ray","year":"2010","unstructured":"Ray JA, Carr E, Lewis G, Marcus R. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin\u2019s lymphoma in the UK. Value Health. 2010;13:346\u201357.","journal-title":"Value Health"},{"key":"612_CR149","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/annonc\/mdq582","volume":"22","author":"EJ Soini","year":"2011","unstructured":"Soini EJ, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin\u2019s lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2011;22:1189\u201397.","journal-title":"Ann Oncol"},{"key":"612_CR150","doi-asserted-by":"publisher","first-page":"978391","DOI":"10.1155\/2012\/978391","volume":"2012","author":"RI Griffiths","year":"2012","unstructured":"Griffiths RI, Gleeson ML, Mikhael J, Danese MD. Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare. J Cancer Epidemiol. 2012;2012:978391.","journal-title":"J Cancer Epidemiol"},{"key":"612_CR151","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.3109\/10428194.2012.694429","volume":"53","author":"J Hornberger","year":"2012","unstructured":"Hornberger J, Chien R, Friedmann M, et al. Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy. Leuk Lymphoma. 2012;53:2371\u20137.","journal-title":"Leuk Lymphoma"},{"key":"612_CR152","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/ejh.12264","volume":"92","author":"HM Blommestein","year":"2014","unstructured":"Blommestein HM, Issa DE, Pompen M, et al. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study. Eur J Haematol. 2014;92:398\u2013406.","journal-title":"Eur J Haematol"},{"key":"612_CR153","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jval.2014.12.017","volume":"18","author":"Q Chen","year":"2015","unstructured":"Chen Q, Ayer T, Nastoupil LJ, Rose AC, Flowers CR. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma. Value Health. 2015;18:189\u201397.","journal-title":"Value Health"},{"key":"612_CR154","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1002\/cncr.29372","volume":"121","author":"A Prica","year":"2015","unstructured":"Prica A, Chan K, Cheung M. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: a cost-effectiveness analysis. Cancer. 2015;121:2637\u201345.","journal-title":"Cancer"},{"key":"612_CR155","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1524-4733.2010.00737.x","volume":"13","author":"KM Johnston","year":"2010","unstructured":"Johnston KM, Marra CA, Connors JM, Najafzadeh M, Sehn L, Peacock SJ. Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada. Value Health. 2010;13:703\u201311.","journal-title":"Value Health"},{"key":"612_CR156","doi-asserted-by":"publisher","first-page":"6079","DOI":"10.1002\/cncr.27638","volume":"118","author":"RI Griffiths","year":"2012","unstructured":"Griffiths RI, Gleeson ML, Mikhael J, Dreyling MH, Danese MD. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer. 2012;118:6079\u201388.","journal-title":"Cancer"},{"key":"612_CR157","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1186\/1471-2407-14-586","volume":"14","author":"S Khor","year":"2014","unstructured":"Khor S, Beca J, Krahn M, et al. Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. BMC Cancer. 2014;14:586.","journal-title":"BMC Cancer"},{"key":"612_CR158","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3109\/10428194.2011.605918","volume":"53","author":"J Hornberger","year":"2012","unstructured":"Hornberger J, Reyes C, Shewade A, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:225\u201334.","journal-title":"Leuk Lymphoma"},{"key":"612_CR159","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40273-013-0125-7","volume":"32","author":"M Adena","year":"2014","unstructured":"Adena M, Houltram J, Mulligan SP, Todd C, Malanos G. Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse. Pharmacoeconomics. 2014;32:193\u2013207.","journal-title":"Pharmacoeconomics"},{"key":"612_CR160","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/CMAR.S79258","volume":"7","author":"O Mandrik","year":"2015","unstructured":"Mandrik O, Corro Ramos I, Knies S, Al M, Severens JL. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine. Cancer Manag Res. 2015;7:279\u201389.","journal-title":"Cancer Manag Res"},{"key":"612_CR161","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3109\/10428194.2015.1070151","volume":"57","author":"D M\u00fcller","year":"2016","unstructured":"M\u00fcller D, Fischer K, Kaiser P, et al. Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 2016;57:1130\u20139.","journal-title":"Leuk Lymphoma"},{"key":"612_CR162","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/MLR.0000000000000486","volume":"54","author":"MD Danese","year":"2016","unstructured":"Danese MD, Reyes CM, Gleeson ML, Halperin M, Skettino SL, Mikhael J. Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real-world data. Med Care. 2016;54:343\u20139.","journal-title":"Med Care"},{"key":"612_CR163","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","volume":"34","author":"K Tobinai","year":"2017","unstructured":"Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther. 2017;34:324\u201356.","journal-title":"Adv Ther"},{"key":"612_CR164","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000381524","volume":"38","author":"V Goede","year":"2015","unstructured":"Goede V, Klein C, Stilgenbauer S. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-Hodgkin\u2019s lymphomas: a glycoengineered type II CD20 antibody. Oncol Res Treat. 2015;38:185\u201392.","journal-title":"Oncol Res Treat"},{"key":"612_CR165","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1756-8722-5-64","volume":"5","author":"S Cang","year":"2012","unstructured":"Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol. 2012;5:64.","journal-title":"J Hematol Oncol"},{"key":"612_CR166","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1182\/blood-2010-04-001230","volume":"116","author":"SM Jaglowski","year":"2010","unstructured":"Jaglowski SM, Alinari L, Lapalombella R, et al. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood. 2010;116:3705\u201314.","journal-title":"Blood"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0612-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0612-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0612-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T16:00:17Z","timestamp":1693065617000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0612-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":166,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0612-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"14 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The information reported in this review is derived from previously conducted studies: this does not include any new studies of human or animal subjects performed by any of the authors. All authors had full access to the information included in this review and take complete responsibility for the integrity of the data discussions.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"Martin Barrett is an employee of Roche Products Ltd. and holds share options. Robin Fo\u00e0 has received honoraria from F. Hoffmann-La Roche Ltd. Joerg Maurer is an employee of F. Hoffmann-La Roche Ltd. and holds share options. Michael Wenger is an employee of F. Hoffmann-La Roche Ltd. and holds share options. David G. Maloney has nothing to disclose. Nancy Valente is an employee of Genentech Inc. and holds share options. Gilles Salles has received research and travel grant support and honoraria from F. Hoffmann-la Roche Ltd., and honoraria from Amgen, BMS, Celgene, Gilead, Janssen, Kite, Merck, Morphosys, Novartis, and Servier. Susan O\u2019Brien has received research grant support from ProNAI, Regeneron, and Acerta, and consultant\/research support from Gilead, Pharmacyclics, TG Therapeutics, and Pfizer, and has acted as a consultant for Amgen, Astellas, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences Inc., Vaniam Group LLC, Abbvie, Sunesis, and Alexion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}